Ashraf Harahsheh1, Sanjeev Aggarwal2, Michael D Pettersen3, Thomas L'Ecuyer4. 1. 1Department of Pediatrics,Division of Cardiology,Children's National Health System,The George Washington University School of Medicine,Washington,District of Columbia,United States of America. 2. 2Department of Pediatrics,Division of Cardiology,Children's Hospital of Michigan,Wayne State University,Detroit,Michigan,United States of America. 3. 3Rocky Mountain Pediatric Cardiology,Denver,Colorado,United States of America. 4. 4Department of Pediatrics,Division of Cardiology,University of Virginia Health System,Charlottesville,Virginia,United States of America.
Abstract
BACKGROUND: Anthracyclines are effective medications for childhood cancer. Their limitation is the risk of cardiomyopathy. Although diastolic dysfunction has been described in patients who received anthracyclines, cardiac monitoring has focused on systolic function, which is abnormal in up to 41% of the patients. We conducted a study to assess diastolic function utilising transmitral inflow Doppler velocities and tissue Doppler imaging in anthracycline-treated children 5 years post-therapy. METHODS: This was a retrospective study on 63 anthracycline-treated patients. Echocardiographic parameters included peak early and late transmitral inflow Doppler velocities (E, A), E/A ratio, E deceleration time, and tissue Doppler imaging early and late diastolic mitral annulus velocities (E', A'), E/E' ratio, and E'/A' ratio. RESULTS: All indices of diastolic function that we measured were normal in the anthracycline-treated patients. CONCLUSION: We conclude that diastolic function assessed by transmitral inflow Doppler velocities and tissue Doppler imaging is normal in anthracycline-treated children 5 years after completion of treatment. Further longitudinal study is needed to determine whether diastolic function becomes abnormal with time in this patient population.
BACKGROUND:Anthracyclines are effective medications for childhood cancer. Their limitation is the risk of cardiomyopathy. Although diastolic dysfunction has been described in patients who received anthracyclines, cardiac monitoring has focused on systolic function, which is abnormal in up to 41% of the patients. We conducted a study to assess diastolic function utilising transmitral inflow Doppler velocities and tissue Doppler imaging in anthracycline-treated children 5 years post-therapy. METHODS: This was a retrospective study on 63 anthracycline-treated patients. Echocardiographic parameters included peak early and late transmitral inflow Doppler velocities (E, A), E/A ratio, E deceleration time, and tissue Doppler imaging early and late diastolic mitral annulus velocities (E', A'), E/E' ratio, and E'/A' ratio. RESULTS: All indices of diastolic function that we measured were normal in the anthracycline-treated patients. CONCLUSION: We conclude that diastolic function assessed by transmitral inflow Doppler velocities and tissue Doppler imaging is normal in anthracycline-treated children 5 years after completion of treatment. Further longitudinal study is needed to determine whether diastolic function becomes abnormal with time in this patient population.
Authors: William L Border; Ritu Sachdeva; Kayla L Stratton; Saro H Armenian; Aarti Bhat; David E Cox; Kasey J Leger; Wendy M Leisenring; Lillian R Meacham; Karim T Sadak; Shanthi Sivanandam; Paul C Nathan; Eric J Chow Journal: JACC CardioOncol Date: 2020-03-17
Authors: Rosaria Sofia; Veronica Melita; Antonio De Vita; Antonio Ruggiero; Alberto Romano; Giorgio Attinà; Lisa Birritella; Priscilla Lamendola; Antonella Lombardo; Gaetano Antonio Lanza; Angelica Bibiana Delogu Journal: Front Oncol Date: 2021-05-14 Impact factor: 6.244